LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
OBIO
Orchestra BioMed Holdings, Inc.
There isn't enough reported data to score OBIO yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
OBIO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
OBIO's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
OBIO PE Valuation
OBIO has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
OBIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect OBIO's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over OBIO on earnings quality, reporting a profit while its opponent remains loss making.
OBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.73 | +$1.08 |
| Q2 2026 | -$0.83 | +$0.99 |
| Q1 2026 | -$0.95 | +$0.82 |
| Q4 2025 | -$1.11 | +$0.55 |
| Q3 2025 | -$1.81 | -$0.22 |
| Q2 2025 | -$1.82 | -$0.26 |
| Q1 2025 | -$1.77 | -$0.31 |
| Q4 2024 | -$1.66 | -$0.18 |
OBIO is still losing money, but far less than before: $0.73 per share over the past year, against $1.82 at its worst in mid-2025.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over OBIO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over OBIO on profitability, with a higher operating margin.
OBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $91K | -89% |
| Q2 2026 | $88K | -89% |
| Q1 2026 | $110K | -87% |
| Q4 2025 | $30.9M | +12120% |
| Q3 2025 | $861K | -13% |
| Q2 2025 | $836K | +7.5% |
| Q1 2025 | $868K | +40% |
| Q4 2024 | $253K | -3.4% |
OBIO's revenue is growing: $91,000 last quarter, down 89% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -25600% | -23241 points |
| Q2 2026 | -25405% | -23093 points |
| Q1 2026 | -20069% | -17889 points |
| Q4 2025 | 22% | +6614 points |
| Q3 2025 | -2359% | -704 points |
| Q2 2025 | -2312% | -145 points |
| Q1 2025 | -2180% | +146 points |
| Q4 2024 | -6592% | -1828 points |
OBIO's operating margin was −25600% last quarter, down 23241 points from the same quarter a year ago, near the bottom of its range since 2023.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over OBIO on cash generation, producing positive trailing cash flow while its opponent burns cash.
OBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$19.9M | -$5.1M |
| Q2 2026 | -$19.6M | -$4M |
| Q1 2026 | -$22.4M | -$5.6M |
| Q4 2025 | -$2.3M | +$11.3M |
| Q3 2025 | -$14.9M | -$1.1M |
| Q2 2025 | -$15.6M | -$5.2M |
| Q1 2025 | -$16.7M | -$3.6M |
| Q4 2024 | -$13.6M | -$2.7M |
OBIO has burned cash in almost every quarter: −$64M over the past year, against −$61M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over OBIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
OBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.3% | +808K shares |
| 1 year | +24% | +12.4M shares |
| 3 years | +83% | +29.4M shares |
| 5 years | +304% | +48.6M shares |
| Available history | +216% | +44.2M shares |
OBIO has 65M diluted shares, up 24% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
OBIO Net Leverage
OBIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
OBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.9 | Neutral |
| Stochastic | 77.1 | Neutral |
OBIO's weekly RSI is 65 (neutral) and its Stochastic is 77 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
OBIO PE vs Healthcare Sector
OBIO has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
OBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.83 | 5.5% above |
| 20 week MA | $5.13 | 20% above |
| 50 week MA | $4.55 | 35% above |
| 100 week MA | $4.09 | 50% above |
| 200 week MA | $6.09 | 1% above |
OBIO has climbed back above all five of its weekly moving averages, and it's now 1% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
OBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.9 | $11.8 | -0.8% |
| 2021 | $11.8 | $9.83 | -17% |
| 2022 | $9.83 | $9.97 | +1.4% |
| 2023 | $9.97 | $9.13 | -8.4% |
| 2024 | $9.13 | $4.40 | -52% |
| 2025 | $4.40 | $4.32 | -1.8% |
| 2026 YTD | $4.32 | $6.15 | +42% |
OBIO has the edge over LLY on returns for 2026, with the stronger performance.